Adamas Pharma Cmn (ADMS) 13.67 $ADMS
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
PR Newswire - Wed Aug 31, 7:00AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
AGN: 234.54 (-2.45), ADMS: 13.67 (+0.68)
Adamas Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the second quarter of 2016.
ADMS: 13.67 (+0.68)
Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Wed Jun 22, 5:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease (PD) at the 20 Annual International Congress of Parkinson's and Movement Disorders in Berlin, Germany. Data was presented from two trials -- EASE LID and EASE LID 2 -- by Rajesh Pahwa, M.D., a recognized expert in PD and LID. Levodopa-induced dyskinesia, which is a condition characterized by involuntary movements without purpose, can become severely disabling, rendering people with Parkinson's disease unable to perform routine daily tasks.
ADMS: 13.67 (+0.68)
Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
GlobeNewswire - Mon Jun 13, 7:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine HCl) extended-release capsules in individuals with multiple sclerosis (MS) who have impaired walking. Data from the study suggest that ADS-5102 is well tolerated in the MS patient population and has a significant positive impact on walking speed. The company plans to present these data at an upcoming scientific conference.
ADMS: 13.67 (+0.68)
Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson's and Movement Disorders
GlobeNewswire - Mon May 16, 5:00PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease, will be highlighted in two poster presentations at the 20 Annual International Congress of Parkinson's and Movement Disorders, being held June 19 to 23, 2016, in Berlin, Germany.
ADMS: 13.67 (+0.68)
Adamas reports 1Q loss
Automated Insights - Tue May 10, 5:01PM CDT
EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Tuesday reported a loss of $13.8 million in its first quarter.
ADMS: 13.67 (+0.68)
Adamas Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 4:07PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016.
ADMS: 13.67 (+0.68)
Adamas Announces New Employment Inducement Grant
GlobeNewswire - Fri May 06, 4:41PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received a grant of an option to purchase 67,500 shares of the company's common stock, at a per share exercise price of $14.70, the closing trading price on May 6, 2016, and 11,250 restricted stock units, pursuant to the terms of her employment agreement with Adamas. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
ADMS: 13.67 (+0.68)
Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients with Parkinson's Disease
GlobeNewswire - Thu Apr 28, 6:04AM CDT
Third Randomized Clinical Trial Meets Primary and Key Secondary Endpoints
ADMS: 13.67 (+0.68)
Adamas to Host Conference Call and Webcast to Provide Company Update
GlobeNewswire - Wed Apr 27, 7:09PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on Thursday, April 28, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a company update.
ADMS: 13.67 (+0.68)
Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease at the American Academy of Neurology Annual Meeting
GlobeNewswire - Tue Apr 19, 7:45PM CDT
Anti-dyskinetic Effect Consistent Across Primary and Secondary Outcome Measures
ADMS: 13.67 (+0.68)
Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting
GlobeNewswire - Thu Apr 14, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology, Director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center, will present emerging science abstract # 014, "ADS-5102 (amantadine HCl) Extended-Release Capsules Reduced Levodopa-Induced Dyskinesia in the Phase 3 EASE LID Study," on Tuesday, April 19, from 5:45 p.m. to 7:15 p.m. PT at the 68 American Academy of Neurology Annual Meeting, being held April 15 to April 21, 2016, in Vancouver, British Columbia.
ADMS: 13.67 (+0.68)
Adamas Pharmaceuticals Provides Review of 2015 and Projected Future Milestones
GlobeNewswire - Tue Jan 12, 3:05PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today is providing a summary of 2015 corporate highlights and planned future milestones. Adamas, which is developing new medicines for chronic neurological disorders, utilizes its technology platform to improve the pharmacokinetics profiles of approved drugs, alone and in fixed-dose combinations. The company is developing ADS-5102 for two indications: levodopa-induced dyskinesia (LID), a complication associated with the treatment of Parkinson's disease, and major symptoms associated with multiple sclerosis (MS) in patients with walking impairment. Adamas also has ADS-4101 in preclinical development for epilepsy (partial onset seizures). In addition, the company has a partnership with Allergan for two approved products, Namzaric(TM) and Namenda XR, which are marketed in the U.S. by Allergan.
AGN: 234.54 (-2.45), ADMS: 13.67 (+0.68)
Adamas Pharmaceuticals (ADMS) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 8:13AM CST
As of late, it has definitely been a great time to be an investor in Adamas Pharmaceuticals Inc (ADMS)
ADMS: 13.67 (+0.68)
Adamas prices public offering at USD23.00 per share
M2 - Thu Jan 07, 3:16AM CST
Biopharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) said on Wednesday that it has priced a public offering of 2,500,000 shares of its common stock.
ADMS: 13.67 (+0.68)
Adamas Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 9:08PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $23.00 per share. Adamas also granted the underwriters a 30-day option to acquire an additional 375,000 shares from Adamas. The offering is expected to close on January 12, 2016, subject to customary closing conditions.
ADMS: 13.67 (+0.68)
Adamas plans public offering of 2.5m common shares
M2 - Wed Jan 06, 4:23AM CST
Biopharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) said on Tuesday that it intends to issue 2,500,000 shares of its common stock in a public offering.
ADMS: 13.67 (+0.68)
Adamas Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jan 05, 6:15AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer 2,500,000 shares of its common stock in an underwritten public offering. Adamas expects to grant the underwriters a 30-day option to acquire an additional 375,000 shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMS: 13.67 (+0.68)
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC® Patent Litigation
PR Newswire - Wed Aug 31, 7:00AM CDT
Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
AGN: 234.54 (-2.45), ADMS: 13.67 (+0.68)
Adamas Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the second quarter of 2016.
ADMS: 13.67 (+0.68)
Adamas Announces Additional ADS-5102 Data for the Treatment of Levodopa-induced Dyskinesia at the International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Wed Jun 22, 5:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease (PD) at the 20 Annual International Congress of Parkinson's and Movement Disorders in Berlin, Germany. Data was presented from two trials -- EASE LID and EASE LID 2 -- by Rajesh Pahwa, M.D., a recognized expert in PD and LID. Levodopa-induced dyskinesia, which is a condition characterized by involuntary movements without purpose, can become severely disabling, rendering people with Parkinson's disease unable to perform routine daily tasks.
ADMS: 13.67 (+0.68)
Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
GlobeNewswire - Mon Jun 13, 7:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive findings from its Phase 2 proof-of-concept study designed to evaluate ADS-5102 (amantadine HCl) extended-release capsules in individuals with multiple sclerosis (MS) who have impaired walking. Data from the study suggest that ADS-5102 is well tolerated in the MS patient population and has a significant positive impact on walking speed. The company plans to present these data at an upcoming scientific conference.
ADMS: 13.67 (+0.68)
Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson's and Movement Disorders
GlobeNewswire - Mon May 16, 5:00PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that data from EASE LID and EASE LID 2, trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease, will be highlighted in two poster presentations at the 20 Annual International Congress of Parkinson's and Movement Disorders, being held June 19 to 23, 2016, in Berlin, Germany.
ADMS: 13.67 (+0.68)
Adamas reports 1Q loss
Automated Insights - Tue May 10, 5:01PM CDT
EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Tuesday reported a loss of $13.8 million in its first quarter.
ADMS: 13.67 (+0.68)
Adamas Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 4:07PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016.
ADMS: 13.67 (+0.68)
Adamas Announces New Employment Inducement Grant
GlobeNewswire - Fri May 06, 4:41PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) Adamas today announced that its new General Counsel and Corporate Secretary, Jennifer Rhodes, received a grant of an option to purchase 67,500 shares of the company's common stock, at a per share exercise price of $14.70, the closing trading price on May 6, 2016, and 11,250 restricted stock units, pursuant to the terms of her employment agreement with Adamas. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
ADMS: 13.67 (+0.68)
Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients with Parkinson's Disease
GlobeNewswire - Thu Apr 28, 6:04AM CDT
Third Randomized Clinical Trial Meets Primary and Key Secondary Endpoints
ADMS: 13.67 (+0.68)
Adamas to Host Conference Call and Webcast to Provide Company Update
GlobeNewswire - Wed Apr 27, 7:09PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on Thursday, April 28, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a company update.
ADMS: 13.67 (+0.68)
Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease at the American Academy of Neurology Annual Meeting
GlobeNewswire - Tue Apr 19, 7:45PM CDT
Anti-dyskinetic Effect Consistent Across Primary and Secondary Outcome Measures
ADMS: 13.67 (+0.68)
Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting
GlobeNewswire - Thu Apr 14, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology, Director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center, will present emerging science abstract # 014, "ADS-5102 (amantadine HCl) Extended-Release Capsules Reduced Levodopa-Induced Dyskinesia in the Phase 3 EASE LID Study," on Tuesday, April 19, from 5:45 p.m. to 7:15 p.m. PT at the 68 American Academy of Neurology Annual Meeting, being held April 15 to April 21, 2016, in Vancouver, British Columbia.
ADMS: 13.67 (+0.68)
Adamas Pharmaceuticals Provides Review of 2015 and Projected Future Milestones
GlobeNewswire - Tue Jan 12, 3:05PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today is providing a summary of 2015 corporate highlights and planned future milestones. Adamas, which is developing new medicines for chronic neurological disorders, utilizes its technology platform to improve the pharmacokinetics profiles of approved drugs, alone and in fixed-dose combinations. The company is developing ADS-5102 for two indications: levodopa-induced dyskinesia (LID), a complication associated with the treatment of Parkinson's disease, and major symptoms associated with multiple sclerosis (MS) in patients with walking impairment. Adamas also has ADS-4101 in preclinical development for epilepsy (partial onset seizures). In addition, the company has a partnership with Allergan for two approved products, Namzaric(TM) and Namenda XR, which are marketed in the U.S. by Allergan.
AGN: 234.54 (-2.45), ADMS: 13.67 (+0.68)
Adamas Pharmaceuticals (ADMS) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 8:13AM CST
As of late, it has definitely been a great time to be an investor in Adamas Pharmaceuticals Inc (ADMS)
ADMS: 13.67 (+0.68)
Adamas prices public offering at USD23.00 per share
M2 - Thu Jan 07, 3:16AM CST
Biopharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) said on Wednesday that it has priced a public offering of 2,500,000 shares of its common stock.
ADMS: 13.67 (+0.68)
Adamas Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 9:08PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $23.00 per share. Adamas also granted the underwriters a 30-day option to acquire an additional 375,000 shares from Adamas. The offering is expected to close on January 12, 2016, subject to customary closing conditions.
ADMS: 13.67 (+0.68)
Adamas plans public offering of 2.5m common shares
M2 - Wed Jan 06, 4:23AM CST
Biopharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) said on Tuesday that it intends to issue 2,500,000 shares of its common stock in a public offering.
ADMS: 13.67 (+0.68)
Adamas Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jan 05, 6:15AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer 2,500,000 shares of its common stock in an underwritten public offering. Adamas expects to grant the underwriters a 30-day option to acquire an additional 375,000 shares. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMS: 13.67 (+0.68)
